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Prevention of encrustation and blockage of
urinary catheters by Proteus mirabilis via
pH-triggered release of bacteriophage†
Scarlet Milo,a Hollie Hathaway,a Jonathan Nzakizwanayo,b Diana R. Alves,bc
Patricia Pe´rez Esteban,d Brian V. Jonesbe and A. Toby A. Jenkins *a
The crystalline biofilms of Proteus mirabilis can seriously complicate the care of patients undergoing
long-term indwelling urinary catheterisation. Expression of bacterial urease causes a significant increase
in urinary pH, leading to the supersaturation and precipitation of struvite and apatite crystals. These
crystals become lodged within the biofilm, resulting in the blockage of urine flow through the catheter.
Here, we describe an infection-responsive surface coating for urinary catheters, which releases a thera-
peutic dose of bacteriophage in response to elevated urinary pH, in order to delay catheter blockage.
The coating employs a dual-layered system comprising of a lower hydrogel ‘reservoir’ layer impregnated
with bacteriophage, capped by a ‘trigger’ layer of the pH-responsive polymer poly(methyl methacrylate-
co-methacrylic acid) (EUDRAGITsS 100). Evaluation of prototype coatings using a clinically reflective
in vitro bladder model system showed that catheter blockage time was doubled (13 h to 26 h (P o 0.05))
under conditions of established infection (108 CFU ml1) in response to a ‘burst-release’ of bacteriophage
(108 PFU ml1). Coatings were stable both in the absence of infection, and in the presence of urease-
negative bacteria. Quantitative and visual analysis of crystalline biofilm reduction show that bacteriophage
constitute a promising strategy for the prevention of catheter blockage, a clinical problem for which there
is currently no eﬀective control method.
Introduction
Catheter-associated urinary tract infection (CAUTI) is the most
common healthcare-associated infection worldwide, accounting
for approximately 150–250 million cases globally per year,1
manifesting as an estimated cost of d125 million per year in
the UK alone.2 Themost severe CAUTI sequelae occur as a result of
infection by the urease-producing motile bacteria Proteus mirabilis
(P. mirabilis), which colonise the catheter surface, forming exten-
sive biofilm communities embedded within an exopolymeric
matrix. P. mirabilis expresses a potent bacterial urease enzyme,
which generates ammonia as a by-product of urea hydrolysis,
thus elevating the pH of the urine and surrounding biofilm.
Under these conditions, local supersaturation and precipitation
of struvite [MgNH4PO46H2O] and apatite [Ca10(PO4)6CO3] causes
accumulation of crystalline aggregates, which become embedded
within the organic matrix surrounding the cells on the luminal
surfaces. The continued development of such biofilms and
accretion of crystalline material leads to the eventual obstruc-
tion of the flow of urine through the catheter. Incontinence can
develop owing to urine leakage around the catheter, and reflux
of infected urine to the kidneys may result in serious sympto-
matic episodes such as pyelonephritis, endotoxic shock and
septicaemia.3–5
A range of approaches have been evaluated to prevent
bacterial attachment and subsequent catheter blockage, including
antiseptic-coated silver alloy6 and antimicrobial impregnated
minocycline and rifampin7 approaches. However, all preventative
measures thus far have proved disappointing in clinical use,8–10
and all available catheter types remain susceptible to infection by
P. mirabilis.11,12 Other attempted approaches include impreg-
nation with nitrofurazone,13 electrical currents,14 release of nitric
oxide,15–17 and modulation of urinary pH to prevent precipitation
of inorganic salts.4 A recent randomised controlled clinical trial
evaluating nitrofurazone-coated catheters alongside silver-coated
and plain catheters concluded that neither of these commercially
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available catheters showed a clinically significant reduction of
infection.18,19 Indeed, international guidelines now state that
the evidence is insufficient to support their use in both short
term (o30 days) and long term (430 days) indwelling cathe-
terisation, and nitrofurazone-coated catheters are no longer
available on the market.8
CAUTI currently presents a worldwide therapeutic problem as,
owing to their prevalence, uropathogenic infection has become
a major contributor to global antibiotic use and resistance.
Infections caused by P. mirabilis are notoriously diﬃcult to
eliminate once established in the catheterised urinary tract,
and often respond poorly to conventional antibiotic therapy.1
Furthermore, infections as a result of P. mirabilis have been
found to persist despite multiple catheter changes, and periods
without catheterisation. A striking study by Sabbuba et al.
showed that the same strain of P. mirabilis colonised one
patient for 121 days despite 8 catheter changes, an 8 day course
of antibiotics, and a 20 day period during which the urinary
tract remained uncatheterised.20
As medical procedures become ever more reliant upon
implanted devices for diagnosis and treatment of infectious
disease, further emphasis is placed on safeguarding antibiotic
therapy as the panacea of modern medicine. However, recent
research has begun to focus on alternative forms of antimicro-
bials in the battle against bacterial pathogens. One such treat-
ment utilises bacteriophage (phage), the natural predatory viruses
of bacteria that selectively infect, and in the case of lytic phage,
hijack the host’s biosynthetic machinery in favour of viral replica-
tion, causing the bacterium to lyse rapidly.21 Despite pre-dating
the discovery of chemical antibiotics by several decades,22,23
phage therapy was largely supplanted by its chemical successor.
Today, interest in phage therapy is undergoing a revival as the
antibiotic paradigm shift occurs throughout western medicine
and several advantages over conventional therapeutics have
been recognised, including high strain specificity (therefore
unlikely to disturb normal flora),24,25 self-replication (facilitating
low-dosage treatment),26 and easy manipulation of the phage
genome (providing the possibility of ‘designer’ engineered phage
to treat problematic infections27). Although phage resistance has
been reported, largely owing to changes in phage-receptor
molecules,28,29 this may be oﬀset via the use of phage ‘cocktails’,
where multiple strains of phage are directed against the target
species.21,30–32
One of the major challenges in determining the eﬀect of a
therapeutic agent comes in achieving adequate local delivery to
the site of infection. Often, controlled drug delivery systems rely
on sustained passive delivery, although this often results in
exposure of bacterial pathogens to sub lethal doses of chemical
antibiotics, thus potentially contributing to the continued develop-
ment of multidrug resistant species.33,34 Recently, emphasis
has been placed on developing methods of active, or triggered
release of antimicrobial agents in response to external stimuli
(e.g. pH,35–37 temperature,38,39 or biomarker signals40), in order
to achieve a ‘burst response’ of the active cargo. Triggered
release formulations can be used to reduce the amount of drug
necessary to cause the same therapeutic effect in patients,
as well as ensuring that the cargo is released only in the
physiological location required, thus reducing systemic dosage
and its associated complications.41
Previous studies investigating the ability of phage to reduce
P. mirabilis biofilm biomass, either by entropic confinement of
phage within a hydrogel, or simple administration of phage within
an aqueous suspension has resulted in significant reduction
P. mirabilis populations.21,30,31,42 However, despite the success-
ful outcomes of these investigations, the issue of formulating a
working triggered release system has not been addressed.
We have previously reported a novel infection-responsive
surface coating that utilises urinary pH elevation to provide a
visual warning of catheter blockage by P. mirabilis biofilms. The
dual-layered polymeric coating consisted of a lower hydrogel
‘reservoir’ layer (poly(vinyl alcohol)), employed to encapsulate
the self-quenching dye 5(6)-carboxyfluorescein. This was capped
and sealed by an upper layer of the pH-sensitive polymer
EUDRAGITsS 100 (an anionic co-polymer of methacrylic acid
and methyl methacrylate). Elevation of urinary pH facilitated the
swelling of the upper EUDRAGITsS 100 layer, resulting in the
release and consequent fluorescence switch on of the carboxy-
fluorescein contained in the lower hydrogel matrix. The sub-
sequent visual colour-change of the urine provided a clear visual
signal throughout the closed drainage system of imminent
catheter blockage.43
The aim of this study was to evaluate the potential for
triggered phage delivery from an infection-responsive coating,
in response to an increase in urinary pH by P. mirabilis. Though
there is potential for this technology to be translated to deliver
a variety of antimicrobial agents, the use of lytic bacteriophage
was employed in this work in order to evaluate the eﬃcacy of a
biological antimicrobial in inhibiting catheter blockage. The
potential for bacteriophage to constitute an eﬀective counter-
measure for such a severe consequence of long-term indwelling
catheterisation has a wide-reaching impact, not only on improve-
ment of patient health and welfare, but also in extending
catheter life, thus reducing associated healthcare costs. Proto-
type coatings were evaluated using a clinically relevant in vitro
bladder model system, in which the sterile closed drainage
system was replicated and the catheterised urinary tract accu-
rately represented.
Materials and methods
Materials
Triethyl citrate, talc, Luria-Bertani (LB) broth, Tryptic Soy Broth
(TSB), Tryptic Soy Agar, (TSA), yeast extract, vegetable peptone
number 1, tryptone, sodium chloride, magnesium sulphate,
Tris–hydrochloride (pH 7.5), gelatine, acetone, isopropanol,
sodium hydroxide, anhydrous sodium sulphate, magnesium
chloride hexahydrate, tri-sodium citrate, sodium oxalate,
potassium di-hydrogen orthophosphate (potassium phosphate
monobasic), potassium chloride, ammonium chloride, calcium
chloride, urea, 5(6)-carboxyfluorescein, poly(vinyl alcohol)
(MW 14 600–18 600 g mol
1), and agarose were all purchased
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from Sigma-Aldrich (Poole, Dorset, UK). Bacteriological agar
was obtained from Oxoid, (Basingstoke, Hampshire, UK).
Eudragit S100 was kindly donated by Evonik Industries,
Darmstadt, Germany. Uncoated all-silicone Foley catheters were
obtained from Bard (Crawley, West Sussex, UK).
Material preparation
Silanisation of Foley catheters. Silanisation was performed
according to protocol described in Milo et al.43 in order to
increase surface hydrophilicity. Briefly, catheters were washed
in a 1 : 1 mixture of ammonia (33% v/v) and hydrogen peroxide
(30% v/v) for 10 minutes with constant shaking, then rinsed
with sterile deionised water and dried under nitrogen. Catheters
were then placed in (3-aminopropyl triethoxysilane) (APTES)
(1% v/v) in N,N-dimethylformamide (DMF) for 16 h. Surface
modified catheters were rinsed with DMF, followed by sterile
deionised water and dried under nitrogen. Water contact angle
measurements were made to ensure the hydrophilicity of the
catheter surface.
PVA hydrogel preparation. Poly(vinyl alcohol) (PVA, Mw
14 600–18 600 gmol1, 20% w/v) was dissolved in deionised
water and heated to 97 1C with constant stirring to facilitate
dissolution.
EUDRAGITsS 100 dip-coating solution preparation.
EUDRAGITsS 100, with a ratio of free carboxyl groups: ester
groups of 1 : 2, and an averagemolecular weight of 150000 gmol1
was used (Evonik Industries, Germany). The organic dip-coating
solution was prepared according to the technical information44 as
described previously.43 The solution was stored at room tempera-
ture until required.
Coating of Foley catheters
To the cooled PVA solution (20 1C) was added high titre phage
lysate (1010 plaque-forming units per ml (PFU ml1)) at a 1 : 1
ratio, to form a final PVA concentration of 10% w/v. Catheters
were coated with the gel/phage solution (100 ml) between the
retention balloon and the tip, and stored overnight at 20 1C to
promote cryogenic gelation. Catheters were thawed at room
temperature (2 hours) before coating with the pH-sensitive
trigger layer. Catheters were manually dip-coated 20 times in
the EUDRAGITsS 100 solution, with a 5 minute solvent evapo-
ration period between each coating, to achieve a final coating
thickness of approximately 500 mm. Coated catheters were
stored at 4 1C until required.
Microbiology
Bacterial strains, media and routine culture. Bacterial iso-
lates (strain B4) were obtained from a previously acquired
collection of strains belonging to the Jones group (School of
Pharmacy and Biomolecular Sciences, University of Brighton),
which were previously isolated from the urine or catheters
of patients undergoing long-term urinary catheterisation.45
Escherichia coli (strain DH5a) was obtained from a previously
acquired collection housed at the University of Bath. Bacteria
were routinely cultured in Luria-Bertani (LB) broth medium at
37 1C either with shaking or on Non-Swarming LB (NSLB) agar
(5 g l1 yeast extract, 10 g l1 tryptone, 15 g l1 bacteriological
agar). Soft agar overlays were used for phage enrichments, puri-
fication and enumeration, and performed with NSLB-derived agar
(i.e. S-NSLB) (5 g l1 yeast extract, 10 g l1 vegetable peptone,
5.75 g l1 bacteriological agar). S-NSLB was kept molten at 50 1C
for use in double agar overlay. Bacteriophage resuspension was
performed in SM buﬀer (100 mM NaCl, 10 mM MgSO47H2O,
50 mM Tris–HCl). The solution was supplemented with 0.01%
gelatine to aid stability of phage during storage.
Bacteriophage isolation and purification. Bacteriophage
was isolated from crude sewage (Hailsham North WWTP, East
Sussex, UK) according to a previously described protocol.46
Details of microbiological methods can be found in the ESI.†
In vitro bladder models. Assembly and operation of bladder
models was followed according to Milo et al.43 The model con-
sists of a double chambered glass vessel maintained at physio-
logical temperature via an external water jacket. After sterilisation
via autoclaving, coated catheters were inserted aseptically into the
vessel via the glass outlet at the base. The catheter retention
balloon was inflated using sterile water (10 ml), and a sterile
drainage bag (Bard, UK) attached to complete the closed catheter
drainage system. Sterile artificial urine was supplied to the system
via a peristaltic pump at a psyiological flow rate of 0.75mlmin1.47
For simulation of infection, residual urine in the models was
directly inoculated with P. mirabilis or E. coli bacteria cells
(108 CFU ml1), using strains B4 and DH5a, respectively. The
bacterial cultures were allowed to establish within the bladder
model for 1 hour before flow of artificial urine was restored.
Numbers of viable bacterial cells, as well as bacteriophage con-
centration, was enumerated at periodic intervals throughout
the experiments, along with pH readings, via direct sampling of
the medium within the bladder.
Microbiological quantification. Quantitative analysis of viable
bacterial cells and phage populations was performed from
cultures removed directly from bladder models (10 ml). For
bacteria, serial dilutions of the original culture were performed
(101–108), plated in triplicate on NSLB agar, and incubated
for 18 hours (37 1C). Colony counting was used to estimate
cell numbers and expressed as colony forming units per ml
(CFU ml1). For phage, original culture was first filter sterilised
(0.22 mm) to remove bacteria, then serial diluted (101–108)
and plated in a double agar overlay. Phage solution (100 ml), was
added to growing culture of P. mirabilis B4 (100 ml) and mixed
with S-NSLB agar, then poured onto an NSLB agar plate and
incubated statically for 18 hours at 37 1C. Phage enumeration
was performed via plaque-counting and concentration of phage
expressed in PFU ml1.
Analysis
Quantification of crystalline calcium concentration within
catheter biofilms. Biofilm biomass was quantified at the conclu-
sion of each experiment by analysis of calcium concentration
within the crystalline biofilms using Atomic Absorption Spectro-
scopy (AAS). Catheters were removed from bladder models at the
time of control blockage (13 hours after model start), and cut
into 1 cm sections. Catheter sections were soaked in nitric acid
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(4% v/v) for 24 hours, following sonication (44 kHz, 5 minutes)
to facilitate diﬀusion of crystals embedded within the catheter
biofilm. The resulting solution was assayed for calcium using a
Perkin Elmer AAnalyst 100 spectrometer (nitrous oxide/acetylene
flame, 422.7 nm) using a combined calcium and magnesium
hollow cathode lamp (S & J Juniper & Co) Where necessary,
samples were diluted further (4% v/v HNO3) to ensure that con-
centration lay within the experimental range (1–5 ppm). Linear
calibration of the AAS was performed via dilution of standard
Ca2+ solutions (BDH Prolabo) with 2000 ppm potassium (as KCl)
as ionisation suppressant.
SEM imaging of catheter cross-sections. Catheter sections
were mounted directly on to aluminium stubs using adhesive
carbon tabs (Agar Scientific, Stanstead, UK). Mounted sections
were stored under vacuum for 12 hours, sputter coated with
gold and imaged via a Scanning Electron Microscope (SEM)
(JEOL JSM6480LV operated at 10 kV).
Analysis of data. All statistical analysis was performed using
Prism 7.02 for Windows (GraphPad Software Inc., USA; http://
www.graphpad.com). Data were analysed using one-tailed unpaired
Student’s t test. Quoted P values represent statistical significance at
a 95% confidence level.
Results and discussion
In this study, the potential for bacteriophage as an eﬀective
countermeasure for encrustation and blockage of urinary catheters
was investigated. Previous work developed an infection-responsive
coating for diagnosis of CAUTI, showing that molecules of the self-
quenching dye 5(6)-carboxyfluorescein can be successfully incor-
porated into a hydrogel coating and released in response to
elevated urinary pH caused by P. mirabilis infection.43
In vitro infection models for evaluation of prototype coatings
To evaluate the ability of the dual-layered polymeric coating to
delay catheter blockage, performance was assessed using the
in vitro bladder model system (Fig. S1, ESI†), originally described
by Stickler et al.48 This model provides an accurate physiological
representation of the catheterised urinary tract, mimicking the
full closed drainage system currently used in clinical practice. In
comparison, previous studies have utilised simple static models
of biofilm formation on catheter sections,21 flow models that
use only the central catheter lumen,31,42 or those that do not
accurately represent the full closed drainage system. Whilst
these studies have provided fundamental information about
the general properties of biofilm formation and the success of
various treatment options, the in vitro bladder models used in
this study assess biofilm formation and catheter blockage
under conditions in which the design features of the catheter
and the hydrodynamics of the catheterised bladder are taken
into consideration.
Experiments assessing the stability and eﬃcacy of proto-
type coatings were carried out using out an initial P. mirabilis
inoculum of 108 CFU ml1. This was a simulation of an estab-
lished infection, therefore testing the coatings under conservative
‘worst case scenario’ conditions. Furthermore, bladder model
inoculums were left to establish for 1 hour before urinary flow
was restored, meaning that coatings were tested under estab-
lished biofilm conditions rapidly after model start. Although this
resulted in a delay of catheter blockage, rather than a complete
prevention (which has been observed previously via use of a lower
starting inoculum),30 it provides a far more accurate representa-
tion of the bladder during long-term indwelling catheterisation,
particularly after a catheter change, where colonisation by
P. mirabilis may already be established within the bladder.
Activation of catheter coating: eﬀect on catheter blockage
In order to evaluate the capacity of the triggered-release bacterio-
phage coating to delay catheter blockage and reduce biofilm
biomass on the luminal surfaces, pH of artificial urine media,
bacteriophage release and consequent reduction in viable
bacterial population were monitored quantitatively throughout
the course of the bladder model experiments. Regular measure-
ments at 0, 2, 4 and 6 hours after model start served to observe
changes in the biological and chemical conditions within the
bladder models during crystalline biofilm formation, whilst
the final measurement was made at the point of blockage of the
uncoated control (13 hours after model start), and served to
compare the conditions within the bladders containing coated
and uncoated catheters at this point.
The blockage of the catheters and subsequent stemming of
artificial urine flow was defined as the experimental end-point.
Parallel experiments evaluating the response of the coating to
infection by E. coli were also undertaken, in order to determine
the ability of the system to discriminate between urease posi-
tive (P. mirabilis), and urease negative (E. coli) species. Since
E. coli species are the most commonly encountered pathogens
within the urinary tract (including the early stage colonisation
of the catheterised urinary tract), diﬀerential switch-on of the
phage release coating is essential, in order for the burst release
of phage to be of suﬃcient concentration during the later-stage
colonisation of P. mirabilis.49 During the experiments, no
significant phage release was observed in models devoid of
P. mirabilis. Indeed, coatings remained intact to the naked eye in
uninoculated models, as well as those infected with the urease
negative pathogen. Further controls evaluating the eﬀect of the
polymeric coating (not containing phage) were also performed in
parallel. No significant eﬀect on urinary pH, bacterial population
or time to blockage was observed in the presence of the dual-
layered coating in comparison to uncoated catheters. Graphical
representation of the change in urinary pH, CFU ml1 and
PFU ml1 including full experimental controls can be observed
in the ESI† (Fig. S2–S4).
Inoculation with P. mirabilis and subsequent urease produc-
tion caused a substantial increase in pH within two hours of the
model start, owing to the expression of urease from P. mirabilis
and production of ammonia within the urine. Consequent
formation of the carboxylate anion results in swelling of the
EUDRAGITs network, thereby exposing the PVA reservoir layer
to the artificial urinemedia, resulting in release of bacteriophage
from the coating via diﬀusion (Fig. 1).
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Since the threshold pH for EUDRAGITs swelling occurs at
pH 7,44 elevation of urinary pH above this value results in a
burst response of phage from the coating (P = 0.0008). The con-
centration of phage released after 2 hours (4.3  108 PFU ml1)
(P = 0.0048) is suﬃcient to cause bacterial cell death according
to previous experiments investigating eﬃcacy of infection and
replication of phage against P. mirabilis (data not shown), and
corresponded to a urinary pH change of 2 pH units, from the
‘healthy’ 6.24 to the infected 8.24 after 2 hours. The elevated pH
was maintained within the uncoated control bladder, even-
tually resulting in blockage after 13 hours, indicating the speed
at which biofilm formation occurs once an infection is estab-
lished. In contrast, a reduction of urinary pH back into the
healthy range was observed post-release in the phage-coated
catheter model. Gradual decrease of the phage population
within the bladder model, and hence the failure of the coating
to prevent catheter blockage altogether is due primarily to the
elution of particles from the bladder post-release (as confirmed
by titre measurements of residual bag urine upon completion
of the experiment). Controls exhibited negligible phage release
throughout all measured time points, indicating the stability
of the catheter coating for the duration despite exposure to a
continuously flowing culture.
Notable also is the stability of the phage within the coating,
which remained viable throughout the entire experimental
procedure, including encapsulation within the hydrogel reservoir,
coating with an organic polymeric mixture, storage at 4 1C, and
exposure to the challenging conditions of the bladder (involving
both neutral and alkaline pHs, as well as the high ionic strength of
the urine media). Phage stability with respect to clinical applica-
tion is considered to be a barrier to their eventual use within the
clinical setting,50 hence the proof of stability within a hydrogel
matrix, as well as the maintenance of infectivity in the face of more
representative physiological conditions presented in this work
signify the successfully maintained viability of the viruses despite
the removal of the phage from its natural conditions and exposure
to experimental interferents.
As a result of triggered phage release from the catheter coatings,
a significant decline in the bladder-dwelling P. mirabilis concen-
tration was observed (Fig. 2) (P = 0.0016). Decline in viable cell
numbers can be seen to be proportional with the release profile of
phage from coated catheters. In contrast, bladders containing
uncoated catheters sustained cell populations in the region of
108 CFU ml1, leading to eventual blockage of the catheter lumens
via the crystalline biofilms of P. mirabilis. Fig. S2 (ESI†) shows that
no significant changes in bacterial cell numbers were observed in
the presence of the dual-layered coating not containing phage,
indicating that any reduction in cell numbers is as a direct result of
lysis via phage infection.
Nevertheless, despite an approximately 6-log reduction in
P. mirabilis concentration within 2 hours of coating activation,
Fig. 1 Analysis of in vitro bladder model conditions at regular intervals after
model start (0, 2, 4, 6 hours), and at the blockage time of the uncoated
control (13 hours). (A) Measured pH of residual bladder model urine.
***Po 0.001. (B) Release of bacteriophage (j) from the catheter coating.
**P o 0.005. Data shown is the mean of triplicate repeats. Error bars
represent standard error of the mean (SEM).
Fig. 2 Analysis of P. mirabilis population within in vitro bladder models
(containing uncoated and phage (j) coated catheters) at regular intervals
after model start (0, 2, 4, 6 hours), and at the blockage time of the uncoated
control (13 hours). **Po 0.005. Data shown is the mean of triplicate repeats.
Error bars represent standard error of the mean (SEM).
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triggered phage release was successful only in delaying catheter
blockage, not preventing it completely. The gradual increase in
CFU ml1 between 4–13 hours after model start is likely due to
the proportional elution of phage form the bladders observed
previously. However, it is also possible that the failure to
prevent blockage was multifactorial, and that the development
of resistance to the phage used also contributed to the eventual
crystalline biofilm formation. The emergence of resistance may
be associated with a number of different factors which affect
the rate of phage adsorption to the bacterial host, including
alteration of the structure or exposure of the receptor site,
restriction modification, or other mechanisms of abortive infec-
tion such as the presence of clustered regularly interspaced short
palindromic repeats (CRISPRs) within the bacterial genome.51
Although comparable resistance has been observed in other
studies of phage therapy over a similar time frame,52 the fact
that this proof-of-concept study utilised a single phage for ease
of measurement is worth noting. The issue of resistance to
phage may be eased by the use of phage ‘cocktails’, where two
or more species of phage are used to target and significantly
reduce biofilm formation in a number of applications. Indeed,
treatment of uropathogenic isolates with phage cocktails have
shown recent success in vitro,21,30,52 although ensuring an effec-
tive cocktail of strains requires detailed study into host range
profiles, and in-depth understanding of phage-host interaction
and binding under conditions encountered within the cathe-
terised urinary tract. Additionally, recent advances in therapy
using bacteriophage products, namely bacteriophage-encoded
endolysins, which are utilised in end stages of phage infection,
and care capable of enzymatically degrading the bacterial cell
wall through digestion of the peptidoglycan polymeric material,
resulting in cell death by osmolysis.38 Endolysins have been use
synergistically with antibiotics to give increased antibiotic activity
against otherwise resistant Gram-negative strains.53 Other factors
potentially hindering phage efficacy include the inhibition of
phage adhesion to their bacterial hosts owing to the accumula-
tion of struvite and apatite crystalline precipitates, or the physio-
logical state of the cells themselves, since log-phase cells are lysed
more efficiently than those in a state of partial or full metabolic
quiescence (such as those within a biofilm).54 As a consequence
of the phage burst response and subsequent reduction in viable
cell count of P. mirabilis, time to blockage of the phage coated
catheter was doubled in comparison to the uncoated control
(Fig. 3) (P = 0.0199).
Our findings were in agreement with previous studies which
assessed the ability of lytic bacteriophage to reduce catheter
biofilms caused by common uropathogenic species including
P. mirabilis, E. coli, Pseudomonas aeruginosa and Staphylococcus
epidermis.21,30,31,42,52,55–57 Former investigation into the impact
of bacteriophage therapy on an early infection model (starting
inoculum of 103 CFU ml1) have shown a delay in catheter
blockage of more than 8 days.30 Hence, the blockage delay
presented in this work may translate to days, rather than hours,
when assessed using early-stage colonisation. Achieving such
delay of catheter blockage has the potential to improve the
health and welfare of many patients worldwide, as well as
relieve some of the substantial demand that this issue places
on the resources of the health service. Currently, there are no
effective strategies for preventing catheter encrustation and
blockage. Prophylactic treatment of bacteriuria with systemic
antibiotics is strongly discouraged, owing to the development
of multidrug resistance. Indeed, the most effective preventative
strategy developed to date in the implementation of a closed
drainage system, which was introduced almost a century ago.58
Hence, the successful application of targeted release phage
in vitro, which is able to delay catheter blockage whilst both
avoiding systemic treatment and the use of chemical antibiotics
represents a major step forward in providing an effective solution
for infections of this type.
Activation of catheter coating: eﬀect of crystalline biofilm
formation
Visual examination of biofilm formation of catheter surfaces
showed a marked reduction of biofilm biomass on those coated
with phage. Models containing uncoated and coated catheters
were halted after 13 hours (blockage time of control) and
catheter sections from varying luminal locations were viewed
using SEM (Fig. 4).
At the time of blockage of the uncoated control catheters,
which showed prominent encrustations, the phage-coated catheters
can be seen to be devoid of visible biofilm deposits. The average pH
of residual bladder urine at this time point was 6.77, which was
evidently insuﬃcient to cause precipitation of struvite and apatite
salts within the urine.
Quantification of crystalline biofilm formation at this time
point was performed using AAS (Fig. 5). The presence of low
levels of calcium apatite in the biofilms of the phage-treated
bladder was confirmed using AAS, despite it being invisible in
the visual SEM results. This is likely due to the distinct stages
of P. mirabilis forming its complex crystalline biofilms as
Fig. 3 Impact of bacteriophage treatment on catheter blockage. In vitro
models of the catheterised urinary tract replicating established P. mirabilis
infection were used to evaluate the impact of triggered phage (j) release
on blockage and encrustation. The time at which the catheters became
blocked and urine ceased to accumulate in the drainage bags was used as
the experimental end point. Data represents the mean of 3 independent
replicates. *P o 0.05. Error bars represent standard error of the mean
(SEM).
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recently described,59 which suggest that accumulation of diﬀuse
crystalline material accumulates within the bladder before defined
crystals become embedded within the biofilm.
The ability of bacteriophage to mitigate the growth of
P. mirabilis biofilms observed in this work is in agreement with
previous research into phage eﬃcacy in this setting,21 where
the use of a phage cocktail to eradicate E. coli and P. mirabilis
biofilms showed promise. Significant reductions in E. coli bio-
film populations (3–4 log) were observed, however only a 1 log
reduction was observed for P. mirabilis. It was suggested that
the possible reason for this reduced efficacy may be related to
phage-dependent factors such as the production of depoly-
merases and the penetration of the extracellular matrix. More
recently, evaluation of phage cocktails on P. mirabilis biofilms,31
and pre-treated hydrogel silicone catheters to prevent adhesion
of P. aeruginosa and P. mirabilis42 have showed a 1 log, and
approximately 2 log reduction in P. mirabilis (single and mixed
species) populations respectively. The significantly greater 6-log
reduction observed here is likely owing to the initiation of a
burst response from the polymeric film, resulting in exposure of
viable phage particles to exponential growth-phase bacterial cells
and subsequent rapid and substantial decline in bacterial popu-
lation, owing the successful administration of phage after the
‘proliferation threshold’ necessary for active phage treatment.60
Additionally, limitations on cocktail utility have been described
previously.61 Whilst it is logical to assume that phage cocktails
are inherently more effective against bacterial populations in
comparison to monophages, in reality the potential for mixed
coinfections, and the limitations of the cocktails to inhibit
bacterial resistancemay in fact hinder phage productivity. Hence,
it is possible that phage cocktails used in previous studies may
not have used compatible phage types, resulting in reduced
infection robustness or interference by one or more of the
participating phage types. Indeed, treatment via phage cocktail
may not effectively prevent the development of phage-resistant
mutant populations. Such populations will not be present in
sufficiently high densities to support phage amplification able
to control population growth. Once the phage-resistant bacteria
have replicated enough to support active phage treatment, then
cocktail use against them will be equivalent to the primary
treatment. Such secondary treatment is only possible if phage
types are supplied either in sequential doses or continuously.61
Nevertheless, development of suitable, compatible phage cock-
tails is essential for the future of in situ phage therapy such as
the work described here, although an in-depth understanding
of phage kinetics, interference, competition and synergy is
required first in order to produce an effective treatment with
a broad host-range and lower likelihood of resistance evolution.
Conclusion
In summary, this study demonstrates the potential of phage
therapy in the control of CAUTI, in particular the delay of
blockage caused by P. mirabilis device colonisation. Delivery of
therapeutic phage to the infected catheter was achieved locally
via the formulation of a dual-layered polymeric architecture
consisting of a lower ‘reservoir’ layer of PVA hydrogel (contain-
ing phage), capped by an upper ‘trigger’ layer of the copolymer
EUDRAGITsS 100, which has been deemed safe for human
consumption and is already used in the manufacturing of drug-
loaded enteric delivery vehicles.62 This has been demonstrated
by an approximately 6-log reduction of cells within the in vitro
bladder model system after coating initiation via increased
urinary pH. Reduction in bacterial population and subsequent
prevention of struvite and apatite crystal aggregation after
Fig. 4 SEM visualisation of catheter cross-sections comparing levels of
encrustation and blockage by P. mirabilis. (A and C) Uncoated control.
(B and D) With dual-layered bacteriophage coating. All catheters were
removed from in vitro bladder models 13 hours after model start. (A and B)
Show cross sections of catheter eyeholes. (C and D) Show cross sections
of catheter lumen 1 cm below retention balloon.
Fig. 5 Quantitative analysis of crystalline biofilm biomass on catheter
surfaces by Atomic Absorption Spectroscopy (AAS). Comparison of uncoated
and phage (j) coated catheters 13 hours post-inoculation with P. mirabilis.
***P o 0.001. Data shown is the mean of triplicate repeats. Error bars
represent standard error of the mean (SEM).
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phage treatment in situ was successful in doubling the time to
catheter blockage, thus increasing catheter lifetime and poten-
tially reducing the likelihood of serious symptomatic episodes
within patients undergoing long-term indwelling catheterisation.
Bacteriophage release was achieved in direct response to success-
ful infection of the catheter luminal surfaces by P. mirabilis,
resulting in an infection-responsive ‘burst’ release of phage into
an actively growing bacterial population capable of sustaining
and amplifying phage numbers in situ, without external inter-
ference or treatment administration. Moreover, production and
degradation of the dual-layered polymeric coating was found to
have no impact on bacterial or phage viability within the bladder
models, meaning that any observed killing was resultant exclu-
sively from phage infection. This research represents a novel
delivery system for the delivery of a long-overlooked biological
therapeutic, which shows significant promise in the prevention
of encrustation and blockage of urinary catheters, although
further insight into the development of eﬀective phage cocktails,
as well as phage-biofilm interactions is necessary in order to
prevent blockage via controlled in situ release.
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